Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 113 articles: HTML format

Single Articles

November 2024
1. GOURD E
   Lung cancer rates highest among British Bangladeshi men.
   Lancet Oncol. 2024 Nov 28:S1470-2045(24)00683.
   PubMed    
   
   
   
2. HEINZERLING JH, Mileham KF, Robinson MM, Symanowski JT, et al
   Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
   Lancet Oncol. 2024 Nov 27:S1470-2045(24)00573.
   PubMed     Abstract available
   
   
   
3. FURLOW B
   American Lung Association calls for expanded insurance coverage for lung cancer screening.
   Lancet Oncol. 2024 Nov 21:S1470-2045(24)00670.
   PubMed    
   
   
   
4. THUREAU S, Giraud P, Zalcman G, Vera P, et al
   [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer - Authors' reply.
   Lancet Oncol. 2024;25:e541.
   PubMed    
   
   
   
5. BOWEN JONES S, Cooke S, Belderbos J, Faivre-Finn C, et al
   [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer.
   Lancet Oncol. 2024;25:e540.
   PubMed    
   
   
   
6. XU X, Ye L, Shi J, Li H, et al
   [(18)F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer.
   Lancet Oncol. 2024;25:e539.
   PubMed    
   
   
   October 2024
7. PROVENCIO M, Nadal E, Insa A, Garcia Campelo R, et al
   Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
   Lancet Oncol. 2024 Oct 14:S1470-2045(24)00498.
   PubMed     Abstract available
   
   
   
8. WOLF J, Hochmair M, Han JY, Reguart N, et al
   Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
   Lancet Oncol. 2024;25:1357-1370.
   PubMed     Abstract available
   
   
   August 2024
9. GOURD E
   World's first lung cancer vaccine trial launched in the UK.
   Lancet Oncol. 2024 Aug 30:S1470-2045(24)00324.
   PubMed    
   
   
   
10. ZHAO Y, He Y, Wang W, Cai Q, et al
    Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.
    Lancet Oncol. 2024 Aug 16:S1470-2045(24)00379.
    PubMed     Abstract available
    
    
    
11. VERA P, Thureau S, Le Tinier F, Chaumet-Riffaud P, et al
    Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [(18)F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 t
    Lancet Oncol. 2024 Aug 9:S1470-2045(24)00320.
    PubMed     Abstract available
    
    
    
12. WU YL, Guarneri V, Voon PJ, Lim BK, et al
    Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
    Lancet Oncol. 2024;25:989-1002.
    PubMed     Abstract available
    
    
    
13. TENDLER S, Dunphy MP, Agee M, O'Donoghue J, et al
    Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
    Lancet Oncol. 2024;25:1015-1024.
    PubMed     Abstract available
    
    
    July 2024
14. LAZARATOS AM, Petrecca K, Guiot MC, Jerzak KJ, et al
    CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer.
    Lancet Oncol. 2024;25:e282.
    PubMed    
    
    
    
15. AERTS JG, Belderbos R, Baas P, Scherpereel A, et al
    Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase
    Lancet Oncol. 2024;25:865-878.
    PubMed     Abstract available
    
    
    
16. ZAUDERER MG, Dagogo-Jack I
    Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM trial.
    Lancet Oncol. 2024;25:825-827.
    PubMed    
    
    
    June 2024
17. CHEN L, Zhu XZ, Zhao SJ, Yang QW, et al
    PD-L1 as a predictive factor for non-small-cell lung cancer prognosis.
    Lancet Oncol. 2024;25:e233.
    PubMed    
    
    
    May 2024
18. BURKI T
    EPA ruling to ban chrysotile asbestos.
    Lancet Oncol. 2024;25:537.
    PubMed    
    
    
    April 2024
19. SMIT EF, Felip E, Uprety D, Nagasaka M, et al
    Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
    Lancet Oncol. 2024;25:439-454.
    PubMed     Abstract available
    
    
    March 2024
20. GOULART BHL, Mushti SL, Chatterjee S, Larkins E, et al
    Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis.
    Lancet Oncol. 2024 Mar 5:S1470-2045(24)00040.
    PubMed     Abstract available
    
    
    February 2024
21. RHA SY, Bordia S
    Pembrolizumab plus chemotherapy for advanced gastric cancer - Authors' reply.
    Lancet Oncol. 2024;25:e52.
    PubMed    
    
    
    
22. SCHUTTE T, Derks S, van Laarhoven HWM
    Pembrolizumab plus chemotherapy for advanced gastric cancer.
    Lancet Oncol. 2024;25:e51.
    PubMed    
    
    
    
23. HUANG CY, Wu XB
    Pembrolizumab plus chemotherapy for advanced gastric cancer.
    Lancet Oncol. 2024;25:e50.
    PubMed    
    
    
    January 2024
24. RASHID T, Bennett JE, Muller DC, Cross AJ, et al
    Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study.
    Lancet Oncol. 2024;25:86-98.
    PubMed     Abstract available
    
    
    December 2023
25. LEAL T, Langer C
    Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2023;24:e454.
    PubMed    
    
    
    
26. OLIVIER T, Addeo A
    Tumor Treating Fields therapy in metastatic non-small-cell lung cancer.
    Lancet Oncol. 2023;24:e453.
    PubMed    
    
    
    
27. FURLOW B
    IASLC calls for clinical trials to use tobacco use data.
    Lancet Oncol. 2023;24:1309.
    PubMed    
    
    
    November 2023
28. SCOTT SE, Gildea C, Nicholson BD, Evans RE, et al
    Future cancer risk after urgent suspected cancer referral in England when cancer is not found: a national cohort study.
    Lancet Oncol. 2023;24:1242-1251.
    PubMed     Abstract available
    
    
    
29. DOUMA LH, Lalezari F, van der Noort V, de Vries JF, et al
    Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
    Lancet Oncol. 2023;24:1219-1228.
    PubMed     Abstract available
    
    
    October 2023
30. COOPER WA
    Lessons and opportunities from improved understanding of global lung cancer histological subtypes.
    Lancet Oncol. 2023 Oct 11:S1470-2045(23)00475.
    PubMed    
    
    
    
31. ZHANG Y, Vaccarella S, Morgan E, Li M, et al
    Global variations in lung cancer incidence by histological subtype in 2020: a population-based study.
    Lancet Oncol. 2023 Oct 11:S1470-2045(23)00444.
    PubMed     Abstract available
    
    
    
32. HU X, Wang C, Huang W, Barber SM, et al
    Pembrolizumab monotherapy for advanced chordoma.
    Lancet Oncol. 2023;24:e399.
    PubMed    
    
    
    September 2023
33. FENNELL DA
    Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer.
    Lancet Oncol. 2023;24:946-947.
    PubMed    
    
    
    
34. LEAL T, Kotecha R, Ramlau R, Zhang L, et al
    Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 st
    Lancet Oncol. 2023;24:1002-1017.
    PubMed     Abstract available
    
    
    August 2023
35. OZGUROGLU M, Kilickap S, Sezer A, Gumus M, et al
    First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 tri
    Lancet Oncol. 2023 Aug 14:S1470-2045(23)00329.
    PubMed     Abstract available
    
    
    
36. GOURD E
    Middle-age lung screening for everyone who has smoked.
    Lancet Oncol. 2023;24:838.
    PubMed    
    
    
    July 2023
37. JAYAKRISHNAN B, Burney I, Osman AH, Bennji SM, et al
    Adenocarcinoma of lung presenting as diffuse interstitial lung disease.
    Lancet Oncol. 2023;24:e323.
    PubMed    
    
    
    May 2023
38. O'DOWD EL, Lee RW, Akram AR, Bartlett EC, et al
    Defining the road map to a UK national lung cancer screening programme.
    Lancet Oncol. 2023;24:e207-e218.
    PubMed     Abstract available
    
    
    
39. GHORANI E, Quartagno M, Blackhall F, Gilbert DC, et al
    REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment.
    Lancet Oncol. 2023;24:e219-e227.
    PubMed     Abstract available
    
    
    March 2023
40. MITTAL R, Maikap D, Mishra P, Padhan P, et al
    Sclerotic bone metastasis as initial manifestation of lung adenocarcinoma in a patient with SLE.
    Lancet Oncol. 2023;24:e144.
    PubMed    
    
    
    February 2023
41. DONG YM, Sun SZ, Ding SS, Chen HM, et al
    Pseudoprogression of a cutaneous lung cancer metastasis.
    Lancet Oncol. 2023;24:e102.
    PubMed    
    
    
    December 2022
42. SORSCHER S
    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e529.
    PubMed    
    
    
    
43. GANGULY S, Gogia A
    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e528.
    PubMed    
    
    
    
44. UPRETY D
    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e527.
    PubMed    
    
    
    November 2022
45. WESTEEL V, Zalcman G, Scherpereel A, Milleron B, et al
    Thoracic CT follow-up after non-small-cell lung cancer resection - Authors' reply.
    Lancet Oncol. 2022;23:e486.
    PubMed    
    
    
    
46. GOTO T
    Thoracic CT follow-up after non-small-cell lung cancer resection.
    Lancet Oncol. 2022;23:e485.
    PubMed    
    
    
    
47. WOODARD GA, Boffa DJ, Blasberg JD
    Thoracic CT follow-up after non-small-cell lung cancer resection.
    Lancet Oncol. 2022;23:e484.
    PubMed    
    
    
    
48. HEUVELMANS MA, Oudkerk M
    Thoracic CT follow-up after non-small-cell lung cancer resection.
    Lancet Oncol. 2022;23:e483.
    PubMed    
    
    
    October 2022
49. QIN N, Wang C, Chen C, Yang L, et al
    Association of the interaction between mosaic chromosomal alterations and polygenic risk score with the risk of lung cancer: an array-based case-control association and prospective cohort study.
    Lancet Oncol. 2022 Oct 17. pii: S1470-2045(22)00600.
    PubMed     Abstract available
    
    
    
50. SUBBIAH V, Wolf J, Konda B, Kang H, et al
    Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
    Lancet Oncol. 2022;23:1261-1273.
    PubMed     Abstract available
    
    
    September 2022
51. GOURD E
    New evidence that air pollution contributes substantially to lung cancer.
    Lancet Oncol. 2022 Sep 15. pii: S1470-2045(22)00569.
    PubMed    
    
    
    
52. O'BRIEN M, Paz-Ares L, Marreaud S, Dafni U, et al
    Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
    Lancet Oncol. 2022 Sep 9. pii: S1470-2045(22)00518.
    PubMed     Abstract available
    
    
    August 2022
53. WESTEEL V, Foucher P, Scherpereel A, Domas J, et al
    Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2022 Aug 11. pii: S1470-2045(22)00451.
    PubMed     Abstract available
    
    
    
54. NESTLE U, Delorme S
    What is the best choice of follow-up procedure following resection of lung cancer?
    Lancet Oncol. 2022 Aug 11. pii: S1470-2045(22)00499.
    PubMed    
    
    
    
55. GERALDES FO
    IASLC 2022 World Conference on Lung Cancer.
    Lancet Oncol. 2022 Aug 11. pii: S1470-2045(22)00510.
    PubMed    
    
    
    July 2022
56. ELKRIEF A, Yu H
    Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
    Lancet Oncol. 2022 Jul 28. pii: S1470-2045(22)00449.
    PubMed    
    
    
    
57. LU S, Wu L, Jian H, Chen Y, et al
    Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double
    Lancet Oncol. 2022 Jul 28. pii: S1470-2045(22)00382.
    PubMed     Abstract available
    
    
    
58. SILVA V, Abrao F, Peres S, Rosamilia G, et al
    Prognostic factors in curative intent stage I lung adenocarcinoma: a retrospective hospital-based cohort study.
    Lancet Oncol. 2022;23 Suppl 1:S31.
    PubMed     Abstract available
    
    
    
59. LAYCOCK A, Taylor O, Boardman G, Bentel J, et al
    Discordance between clinical and post-surgical staging of patients with operable non-small cell lung cancer: a retrospective audit of lung cancer surgery with curative intent from a single pathology practice.
    Lancet Oncol. 2022;23 Suppl 1:S24.
    PubMed     Abstract available
    
    
    
60. ZHENG X, Lu T, Wu S, Peng W, et al
    Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis.
    Lancet Oncol. 2022;23 Suppl 1:S13.
    PubMed     Abstract available
    
    
    June 2022
61. RECONDO G, Mezquita L
    Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer.
    Lancet Oncol. 2022;23:695-697.
    PubMed    
    
    
    
62. ANDRE T, Diaz LA Jr, Shiu KK
    Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - Authors' reply.
    Lancet Oncol. 2022;23:e246.
    PubMed    
    
    
    
63. BOMZE D, Mutti L, Goldman A, Markel G, et al
    Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy.
    Lancet Oncol. 2022;23:e245.
    PubMed    
    
    
    
64. FENNELL DA, Nusrat N
    Abemaciclib for malignant pleural mesothelioma - Authors' reply.
    Lancet Oncol. 2022;23:e238.
    PubMed    
    
    
    
65. NARDONE V, Porta C, Giannicola R, Correale P, et al
    Abemaciclib for malignant pleural mesothelioma.
    Lancet Oncol. 2022;23:e237.
    PubMed    
    
    
    
66. ZAUDERER MG, Szlosarek PW, Le Moulec S, Popat S, et al
    EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
    Lancet Oncol. 2022;23:758-767.
    PubMed     Abstract available
    
    
    May 2022
67. GAEBE K, Li AY, Park A, Parmar A, et al
    Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis.
    Lancet Oncol. 2022 May 26. pii: S1470-2045(22)00271.
    PubMed     Abstract available
    
    
    
68. RIEKEN S
    Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases.
    Lancet Oncol. 2022 May 26. pii: S1470-2045(22)00301.
    PubMed    
    
    
    
69. SMITH KER, Mansfield AS
    Validating chemoimmunotherapy in small-cell lung cancer.
    Lancet Oncol. 2022 May 13. pii: S1470-2045(22)00288.
    PubMed    
    
    
    
70. CHO BC, Abreu DR, Hussein M, Cobo M, et al
    Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Lancet Oncol. 2022 May 13. pii: S1470-2045(22)00226.
    PubMed     Abstract available
    
    
    
71. WANG J, Zhou C, Yao W, Wang Q, et al
    Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2022 May 13. pii: S1470-2045(22)00224.
    PubMed     Abstract available
    
    
    April 2022
72. WU YL
    Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC - Author's reply.
    Lancet Oncol. 2022;23:e159.
    PubMed    
    
    
    
73. BI N, Wang Y, Wang L
    Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC.
    Lancet Oncol. 2022;23:e158.
    PubMed    
    
    
    
74. OCHOA-DE-OLZA M, Bourhis J, Coukos G, Herrera FG, et al
    Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
    Lancet Oncol. 2022;23:e157.
    PubMed    
    
    
    
75. CHANG JY, Verma V, Welsh JW, Formenti SC, et al
    Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
    Lancet Oncol. 2022;23:e156.
    PubMed    
    
    
    
76. KINDLER HL, Novello S, Bearz A, Ceresoli GL, et al
    Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
    Lancet Oncol. 2022;23:540-552.
    PubMed     Abstract available
    
    
    
77. OTTAIANO A, Santorsola M, Caraco F, Caraglia M, et al
    Initial tumour burden and hidden oligometastatic disease in phase 3 clinical trials.
    Lancet Oncol. 2022;23:452-454.
    PubMed    
    
    
    
78. ZAUDERER MG, Offin M
    ARCS-M: forging progress from this negative trial in malignant pleural mesothelioma.
    Lancet Oncol. 2022;23:445-446.
    PubMed    
    
    
    March 2022
79. FENNELL DA, King A, Mohammed S, Greystoke A, et al
    Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
    Lancet Oncol. 2022;23:374-381.
    PubMed     Abstract available
    
    
    February 2022
80. MACMANUS M, Hegi-Johnson F
    Overcoming immunotherapy resistance in NSCLC.
    Lancet Oncol. 2022;23:191-193.
    PubMed    
    
    
    January 2022
81. ZHOU C, Wang Z, Sun Y, Cao L, et al
    Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00650.
    PubMed     Abstract available
    
    
    
82. ROSELL R, Cao P
    Promising outlook with sugemalimab in non-small-cell lung cancer.
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00698.
    PubMed    
    
    
    
83. ZHOU Q, Chen M, Jiang O, Pan Y, et al
    Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phas
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00630.
    PubMed     Abstract available
    
    
    
84. SCHOENFELD JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, et al
    Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2022 Jan 13. pii: S1470-2045(21)00658.
    PubMed     Abstract available
    
    
    
85. FENNELL DA, Griffiths G, Ottensmeier C, Hanna GG, et al
    CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply.
    Lancet Oncol. 2022;23:e14-e15.
    PubMed    
    
    
    
86. CORREALE P, Pentimalli F, Nardone V, Giordano A, et al
    CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?
    Lancet Oncol. 2022;23:e13.
    PubMed    
    
    
    December 2021
87. LE PECHOUX C, Pourel N, Barlesi F, Lerouge D, et al
    Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.
    Lancet Oncol. 2021 Dec 14. pii: S1470-2045(21)00606.
    PubMed     Abstract available
    
    
    
88. HENDRIKS LEL, De Ruysscher DKM
    Postoperative radiotherapy in resected N2 non-small-cell lung cancer: Lung ART.
    Lancet Oncol. 2021 Dec 14. pii: S1470-2045(21)00654.
    PubMed    
    
    
    
89. PFEIFFER P, Qvortrup C
    KRAS(G12C) inhibition in colorectal cancer.
    Lancet Oncol. 2021 Dec 14. pii: S1470-2045(21)00652.
    PubMed    
    
    
    
90. TAMMEMAGI MC, Ruparel M, Tremblay A, Myers R, et al
    USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
    Lancet Oncol. 2021 Dec 10. pii: S1470-2045(21)00590.
    PubMed     Abstract available
    
    
    
91. TEN HAAF K
    Risk-based lung cancer screening eligibility criteria: towards implementation.
    Lancet Oncol. 2021 Dec 10. pii: S1470-2045(21)00636.
    PubMed    
    
    
    
92. WILKINSON E
    COVID-19 pandemic to lead to thousands of additional UK lung cancer deaths.
    Lancet Oncol. 2021 Dec 2. pii: S1470-2045(21)00699.
    PubMed    
    
    
    
93. CHANG JY, Verma V, Feng L, Roth JA, et al
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery - Authors' reply.
    Lancet Oncol. 2021;22:e537-e538.
    PubMed    
    
    
    
94. ZHANG J, Liu L, Zhao K, Guo C, et al
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Lancet Oncol. 2021;22:e536.
    PubMed    
    
    
    
95. LUO MS
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Lancet Oncol. 2021;22:e535.
    PubMed    
    
    
    
96. KASHIHARA T
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Lancet Oncol. 2021;22:e534.
    PubMed    
    
    
    
97. ZUCALI PA, Pinto C, Ceresoli GL
    RAMES study: is there really a role for VEGF inhibition in mesothelioma? - Authors' reply.
    Lancet Oncol. 2021;22:e533.
    PubMed    
    
    
    
98. PORTA C, Nardone V, Gray SG, Correale P, et al
    RAMES study: is there really a role for VEGF inhibition in mesothelioma?
    Lancet Oncol. 2021;22:e532.
    PubMed    
    
    
    November 2021
99. SAW SPL, Ong BH, Chua KLM, Takano A, et al
    Revisiting neoadjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2021;22:e501-e516.
    PubMed     Abstract available
    
    
    
100. FENNELL DA, Ewings S, Ottensmeier C, Califano R, et al
     Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
     Lancet Oncol. 2021;22:1530-1540.
     PubMed     Abstract available
     
     
     October 2021
101. KINDLER HL
     Understanding the new therapeutic options for mesothelioma.
     Lancet Oncol. 2021;22:1353-1355.
     PubMed    
     
     
     
102. PINTO C, Zucali PA, Pagano M, Grosso F, et al
     Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
     Lancet Oncol. 2021;22:1438-1447.
     PubMed     Abstract available
     
     
     September 2021
103. LANDMAN A
     2021 World Conference on Lung Cancer.
     Lancet Oncol. 2021 Sep 16. pii: S1470-2045(21)00547.
     PubMed    
     
     
     
104. CHANG JY, Mehran RJ, Feng L, Verma V, et al
     Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
     Lancet Oncol. 2021 Sep 13. pii: S1470-2045(21)00401.
     PubMed     Abstract available
     
     
     
105. LOUIE AV, Tjong MC, Siva S
     Surgery versus SABR for early-stage lung cancer-time to call it a draw?
     Lancet Oncol. 2021 Sep 13. pii: S1470-2045(21)00457.
     PubMed    
     
     
     
106. BURKI TK
     Developments in lung cancer biology in never-smokers.
     Lancet Oncol. 2021 Sep 9. pii: S1470-2045(21)00532.
     PubMed    
     
     
     August 2021
107. HUYNH C, Sorin M, Rayes R, Fiset PO, et al
     Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer.
     Lancet Oncol. 2021;22:1056-1058.
     PubMed    
     
     
     June 2021
108. GAINOR JF, Curigliano G, Kim DW, Lee DH, et al
     Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
     Lancet Oncol. 2021 Jun 9. pii: S1470-2045(21)00247.
     PubMed     Abstract available
     
     
     
109. GRONBERG BH, Langer SW, Nyman J, Halvorsen TO, et al
     Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer - Authors' reply.
     Lancet Oncol. 2021;22:e222.
     PubMed    
     
     
     
110. XIE L, Fan X, Qian B
     Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer.
     Lancet Oncol. 2021;22:e221.
     PubMed    
     
     
     
111. LEVY A, Le Pechoux C, Faivre-Finn C
     Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer.
     Lancet Oncol. 2021;22:e220.
     PubMed    
     
     
     May 2021
112. ALTORKI NK, McGraw TE, Borczuk AC, Saxena A, et al
     Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
     Lancet Oncol. 2021 May 17. pii: S1470-2045(21)00149.
     PubMed     Abstract available
     
     
     
113. SEPESI B, Cascone T
     Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?
     Lancet Oncol. 2021 May 17. pii: S1470-2045(21)00261.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.